Abstract: The itching caused by primary cuticular amyloidosis (PCA) is unbearable, and the response to the treatment is currently poor, which greatly affected the patient's quality of life. In recent years, it has been found that the significant therapeutic effects by systemic use of system dupilumab, upadacitinib, baricitinib, and abrocitinib, as well as local use of tranexamic acid, gabapentin, dimethyl sulfoxide solution, fire needle therapy, and lattice carbon dioxide laser. The update of the treatment of PCA is reviewed in this paper to provide reference for clinical practice.

Key words: primary cutanious amyloidosis, dupilumab, upadacitinib, tranexamic acid